Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 18.29%.

  • Theravance Biopharma's EBITDA Margin rose 931500.0% to 18.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 44.44%, marking a year-over-year increase of 1188400.0%. This contributed to the annual value of 72.92% for FY2024, which is 246600.0% up from last year.
  • Per Theravance Biopharma's latest filing, its EBITDA Margin stood at 18.29% for Q3 2025, which was up 931500.0% from 209.3% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's EBITDA Margin registered a high of 7361.3% during Q3 2022, and its lowest value of 1038.96% during Q1 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 88.29% (2025), whereas its average is 206.33%.
  • As far as peak fluctuations go, Theravance Biopharma's EBITDA Margin soared by 76288600bps in 2022, and later plummeted by -74179400bps in 2023.
  • Quarter analysis of 5 years shows Theravance Biopharma's EBITDA Margin stood at 375.8% in 2021, then skyrocketed by 68bps to 119.0% in 2022, then soared by 70bps to 35.53% in 2023, then tumbled by -38bps to 49.06% in 2024, then soared by 137bps to 18.29% in 2025.
  • Its EBITDA Margin stands at 18.29% for Q3 2025, versus 209.3% for Q2 2025 and 88.29% for Q1 2025.